Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA

Summary by Post Register
SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--Jan 7, 2026-

1 Articles

Post RegisterPost Register
Center

Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA

SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--Jan 7, 2026-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Post Register broke the news in on Wednesday, January 7, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Shanghai, China icon

Shanghai, China

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal